Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib Monotherapy in Moderate to Severe Atopic Dermatitis (China)
CTR20181767Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of abrocitinib in atopic dermatitis (AD), sponsored by Pfizer. Started Nov 2018; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20181767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181767.